source
- Ultragenyx to cut 20% of staff and halve R&D budget as it pivots to commercial salesUltragenyx announced it will reduce its workforce by about 20%, bringing headcount down to roughly 1,000 employees. The cuts follow an earlier 10% reduction announced in February and are part of a…
- Novo falls behind Eli Lilly in market race as investors react to Q3 resultsA year ago the competition between Eli Lilly and Novo was described as the fiercest in the industry. Recent commentary suggests the rivalry has become increasingly one‑sided, with Novo struggling t…